Q-omics provides the consensus-scored ZNF425 profile across patient tissues and cancer cell-line models. ZNF425 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF425 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ZNF425 RNA expression shows 20,236 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KIRC, and ACC as cancer lineages where ZNF425 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF425 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF425 survival associations across molecular data types. ZNF425 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF425 RNA expression–survival associations across cancer types. High ZNF425 expression shows unfavorable associations in READ and ACC, but favorable associations in HNSC, KIRC, LGG and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF425 RNA expression.
This table summarizes ZNF425 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF425. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF425 shows lower tumor expression in KIRC, THCA, UCEC, KICH and HNSC and higher tumor expression in LIHC. The KIRC box plot shows higher ZNF425 RNA expression in normal versus tumor tissue (log2 FC = −0.862, t-test p < 0.001).
This table shows molecular features associated with ZNF425 in patient tissues and cancer cell lines. In patient samples, ZNF425 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF425 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
